To Study Post Covid Symptoms
Not Applicable
- Conditions
- Health Condition 1: U071- COVID 19 virus identified
- Registration Number
- CTRI/2023/07/055278
- Lead Sponsor
- Dr Mahesh Saini
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Whoever give verbal consent for study.
2. Had covid at least 3 months prior to study.
Exclusion Criteria
Having covid infection within 3 months of study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To determine the diseases prevailing in society due to long covid. <br/ ><br>2. Information is lacking on symptoms that persist after recovery from Covid-19. We will asses persistent symptoms in patients who recoverd from COVID-19.Timepoint: 2 weeks, 4 weeks, 6 weeks
- Secondary Outcome Measures
Name Time Method 1. Early diagnosis of diseases which are present in other covid 19 patients.Timepoint: 2 weeks, 4 weeks, 6 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in persistent post-acute SARS-CoV-2 infection (PASC) symptoms observed in CTRI/2023/07/055278?
How do biomarkers like IL-6 or ACE2 expression correlate with long hauler syndrome in CTRI/2023/07/055278 observational data?
What comparative effectiveness studies exist for standard-of-care therapies in managing post-COVID-19 syndrome (U071) symptoms?
Are there novel therapeutic agents targeting SARS-CoV-2-induced immune dysregulation in long haul patient cohorts?
What adverse event profiles are reported in longitudinal studies of post-acute sequelae following confirmed SARS-CoV-2 infection (U071)?